Fulgent Genetics, Inc. FLGT
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -21.51%
- 1 year
- -8.15%
- Open
- 21.50
- Prev close
- 21.68
- Mkt cap
- 567.37M
- Vol
- 201.37K
- Avg vol
- 288.42K
- EPS
- -2.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 20.55
- High
- 21.50
- Forward P/E
- -36.45
- Beta
- 1.51
- Short ratio
- 2.87
- Inst. own
- 54.30%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 19.48
- 200-d avg
- 21.08
- 1y target
- 27.67
News
-
2 months ago benzinga.com
Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $19
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $15 to $19.
3 months ago benzinga.com
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…
-
3 months ago benzinga.com
Fulgent Genetics Lowers FY2026 Adj EPS Guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) Est; Lowers FY2026 Sales Guidance from $350.000M to $330.000M-$340.000M vs $351.900M Est
Fulgent Genetics (NASDAQ:FLGT) lowers FY2026 Adj EPS guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) analyst estimate. Lowers FY2026 sales outlook from $350.000 million to $330.000…
-
3 months ago benzinga.com
Fulgent Genetics Q2 Adj. EPS $(0.58) Misses $(0.46) Estimate, Sales $85.389M Miss $94.000M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.46) by 26.09 percent. This is a 928.57 percent decrease over earnings…
-
5 months ago benzinga.com
Fulgent Genetics' FID-007 Plus Cetuximab Shows 60% Response Rate And 7.2-Month Median PFS In Phase 2 Head And Neck Cancer Study With Favorable Safety Profile
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today…
-
6 months ago benzinga.com
Piper Sandler Reiterates Neutral on Fulgent Genetics, Lowers Price Target to $15
Piper Sandler analyst David Westenberg reiterates Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $30 to $15.
6 months ago benzinga.com
Full Transcript: Fulgent Genetics Q1 2026 Earnings Call
Full Transcript: Fulgent Genetics Q1 2026 Earnings Call
8 months ago benzinga.com
Nasdaq Down Over 1%; Dell Shares Jump After Q4 Results
U.S. stocks down mid-trading, Nasdaq falls 1%. Dow down 1.40%, S&P 500 falls 0.74%. Dell shares up 21% on Q4 earnings.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
8 months ago benzinga.com
Dow Dips Over 600 Points; US Producer Prices Increase In January
US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech down. Producer prices rose in January.
-
8 months ago benzinga.com
Fulgent Genetics Sees FY2026 Adj EPS $(1.45) vs $(0.32) Est; Sees Sales $350.000M vs $356.333M Est
Fulgent Genetics (NASDAQ:FLGT) is looking for FY2026 Adj EPS of $(1.45) vs $(0.32) analyst estimate. sees sales of $350.000 million vs $356.333 million analyst estimate.
8 months ago benzinga.com
Fulgent Genetics Q4 Earnings Assessment
Fulgent Genetics Q4 Earnings Assessment
-
8 months ago benzinga.com
Fulgent Genetics Q4 Adj. EPS $0.16 Beats $0.03 Estimate, Sales $83.336M Miss $85.381M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.03 by 433.33 percent. This is a 300 percent increase over earnings of…
-
8 months ago benzinga.com
Earnings Scheduled For February 27, 2026
Earnings Scheduled For February 27, 2026
-
11 months ago benzinga.com
Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $30
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $21 to $30.
-
12 months ago benzinga.com
Fulgent Genetics Raises FY2025 GAAP EPS Guidance from $(2.10) to $(1.70) vs $(1.94) Est
Fulgent Genetics (NASDAQ:FLGT) raises FY2025 GAAP EPS guidance from $(2.10) to $(1.70) vs $(1.94) analyst estimate..
-
12 months ago benzinga.com
Fulgent Genetics Raises FY2025 Adj EPS Guidance from $(0.35) to $0.30 vs $(0.35) Est; Raises FY2025 Sales Guidance from $320.000M to $325.000M vs $320.118M Est
Fulgent Genetics (NASDAQ:FLGT) raises FY2025 Adj EPS guidance from $(0.35) to $0.30 vs $(0.35) analyst estimate. Raises FY2025 sales outlook from $320.000 million to $325.000 million vs $320.118…
-
12 months ago benzinga.com
Fulgent Genetics Q3 Adj. EPS $0.14 Beats $(0.22) Estimate, Sales $84.069M Beat $81.431M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $(0.22) by 162.78 percent. This is a 54.84 percent decrease over earnings of…
12 months ago benzinga.com
Earnings Scheduled For November 7, 2025
Earnings Scheduled For November 7, 2025
-
1 year ago benzinga.com
Fulgent Genetics Reports Phase 2 Cancer Drug Results Ahead Of ESMO 2025 Presentation
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today…
-
1 year ago benzinga.com
UBS Upgrades Fulgent Genetics to Buy, Raises Price Target to $30
UBS analyst Lu Li upgrades Fulgent Genetics (NASDAQ:FLGT) from Neutral to Buy and raises the price target from $20 to $30.
-
1 year ago benzinga.com
Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $21
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $23 to $21.
1 year ago benzinga.com
Monolithic Power Systems, Workiva, Interface, AppFolio And Other Big Stocks Moving Higher On Friday
Monolithic Power Systems, Workiva, Interface, AppFolio And Other Big Stocks Moving Higher On Friday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
Fulgent Genetics Raises FY2025 Adj EPS Guidance from $(0.65) to $(0.35) vs $(0.55) Est; Raises FY2025 Sales Guidance from $310.000M to $320.000M vs $310.682M Est
Fulgent Genetics (NASDAQ:FLGT) raises FY2025 Adj EPS guidance from $(0.65) to $(0.35) vs $(0.55) analyst estimate. Raises FY2025 sales outlook from $310.000 million to $320.000 million vs $310.682…
-
1 year ago benzinga.com
Fulgent Genetics Q2 Adj. EPS $0.07 Beats $(0.18) Estimate, Sales $81.803M Beat $76.205M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.18) by 138.25 percent. This is a 53.33 percent decrease over earnings of…
-
1 year ago benzinga.com
Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $23
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $16 to $23.
-
1 year ago benzinga.com
Raymond James Reiterates Outperform on Fulgent Genetics, Raises Price Target to $25
Raymond James analyst Andrew Cooper reiterates Fulgent Genetics (NASDAQ:FLGT) with a Outperform and raises the price target from $24 to $25.
-
1 year ago benzinga.com
Fulgent Genetics Affirms FY2025 GAAP EPS Guidance of $(1.95) vs $(1.34) Est
Fulgent Genetics (NASDAQ:FLGT) affirms FY2025 GAAP EPS guidance from $(1.95) to $(1.95) vs $(1.34) analyst estimate..
-
1 year ago benzinga.com
Fulgent Genetics Affirms FY2025 Adj EPS Guidance of $(0.65) vs $(0.66) Est; Affirms FY2025 Sales Guidance of $310.00M vs $310.44M Est
Fulgent Genetics (NASDAQ:FLGT) affirms FY2025 Adj EPS guidance from $(0.65) to $(0.65) vs $(0.66) analyst estimate. Affirms FY2025 sales outlook from $310.00 million to $310.00 million vs $310.44…
-
1 year ago benzinga.com
Fulgent Genetics Q1 Adj. EPS $0.04 Beats $(0.18) Estimate, Sales $73.46M Beat $71.26M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.18) by 122.22 percent. This is a 500 percent increase over losses of…
-
1 year ago benzinga.com
A Peek at Fulgent Genetics's Future Earnings
A Peek at Fulgent Genetics's Future Earnings
-
1 year ago benzinga.com
Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $16
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $22 to $16.
-
1 year ago benzinga.com
Fulgent Genetics Q4 Adj $0.04 Beats $(0.12) Estimate, Sales $76.21M Beat $75.39M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.12) by 133.33 percent. This is a 85.71 percent decrease over earnings of…
-
1 year ago benzinga.com
Earnings Scheduled For February 28, 2025
Earnings Scheduled For February 28, 2025
-
1 year ago benzinga.com
Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $22
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $26 to $22.
-
1 year ago benzinga.com
Fulgent Genetics Raises FY24 Adj EPS Guidance from $(0.30) to $0.33 vs $(0.39) Est; Affirms Sales Guidance Of $280.00M vs $282.16M Est
Outlook:For the full year 2024, Fulgent expects:Core Revenue of approximately $280 millionGAAP loss improvement from approximately ($1.95) per share to approximately ($1.70) per shareNon-GAAP loss…
-
1 year ago benzinga.com
Fulgent Genetics Q3 2024 Adj. EPS $0.31 Beats $(0.15) Estimate, Sales $71.740M Beat $71.718M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $(0.15) by 306.67 percent. This is a 179.49 percent increase over losses of…
-
1 year ago benzinga.com
Uncovering Potential: Fulgent Genetics's Earnings Preview
Uncovering Potential: Fulgent Genetics's Earnings Preview
-
2 years ago benzinga.com
Fulgent Genetics Awarded Contract By The U.S. Department Of Veterans Affairs To Provide Hereditary Cancer, Pharmacogenetic And Other Genetic Testing To Veterans; The Award Is For Up To $99M Over 5-Years, Including Both Hereditary Cancer Testing And Pharmacogenetic Testing
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today…
-
2 years ago benzinga.com
Fulgent To Present Clinical Data For Its Lead Therapeutic Oncology Candidate, FID-007, At ASCO 2024 Annual Meeting
Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ:FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data…
-
2 years ago benzinga.com
Fulgent Genetics Q1 2024 Adj EPS $(0.01) May Not Be Comparable To $(0.32) Estimate, Sales $64.485M Miss $65.363M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.32) by 96.88 percent. This is a 95.45 percent increase over losses of…
-
2 years ago benzinga.com
Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $25
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $28 to $25.